Europe Continuous Glucose Monitoring Systems Market Report, published by Allied Market Research, forecasts that the Europe market is expected to garner $351.7 million by 2021, registering a CAGR of 38.0% during the forecast period 2015 – 2021. Sensors segment is anticipated to generate the highest revenue in the European CGMS market during the forecast period.
The European CGMS market is expected to witness dynamic growth, owing to increasing incidence rates of diabetes, growing per capita healthcare expenditure, and rising disposable income of individuals. In addition, CGMS offers various benefits over conventional glucose monitors such as higher precision, greater sensitivity, and periodic monitoring. CGMS technology is applicable in artificial/bionic pancreas; hence, several CGMS and insulin pump manufacturers focus on the development of novel and advanced CGMS. CGMS can be used across all age groups and various healthcare settings. However, unfavorable reimbursement policies for CGMS are expected to hamper the market growth.
Germany is the leading revenue-generating country, owing to favorable guidelines about pricing and fixed reimbursement budget allocation for CGMs devices. In addition, the European CGMS market is estimated to exhibit significant growth in Norway, Sweden, and Denmark due to advanced diabetes care facilities and robust clinical guidelines and standards for diabetes management.
Key findings of Europe Continuous Glucose Monitoring Systems Market:
- U.K. is projected to grow at the highest CAGR of 40.9% during the forecast period.
- Germany generated one-fourth of the total market revenue in 2015 and are projected to be the maximum revenue generating country till 2021.
- Sensors segment accounted for about two third of the market revenue in 2015 and are projected to exhibit prominent growth during the forecast period.
- U.K., Germany and France contributed over half of the market share in 2015.
For Customized Report: https://www.alliedmarketresearch.com/request-for-customization/862